Articles tagged Astrazeneca

‘Reckless in the extreme’: FDA panel recommends new RSV shot for use in healthy infants

Advisers to the U.S. Food and Drug Administration on Thursday recommended approval of AstraZeneca’s new monoclonal antibody, which the drugmaker said is designed to protect infants and toddlers up to age 2 from respiratory syncytial virus, but medical experts interviewed by The Defender called the move 'reckless' and 'preposterous.'